Don’t missed the confirmed screening of “The Parkinson’s Drug Trial: A Miracle Cure?” – filmed over six years and following a group of volunteers with Parkinson’s as they take part in a groundbreaking medical trial testing a drug called GDNF.
When: Thursday, 28 February 2019, at 9 pm to 10 pm
We are delighted to let you know that the European Journal of Neuroscience, NECTAR and the Cure Parkinson’s Trust Special Issue dedicated to Tom Isaacs will be published online on 8th of February and published in print on the 20th of February. The final list of articles is here:
At the most recent NECTAR Board Meeting at the NECTAR2018 meeting in Paris, NECTAR welcomed its new President Dr Agnete Kirkeby from Copenhagen University. We also welcomed three new NECTAR Board members, Dr Romina Aron-Badin from CEA Paris, Dr Stefano Pluchino from the University of Cambridge and Dr Rebecca Matsas from Hellenic Pasteur Institute. Welcome everyone and wishing you the very best in your new role Agnete!
We are delighted to let you know that several articles for the European Journal of Neuroscience, NECTAR and the Cure Parkinson’s Trust Special Issue dedicated to Tom Isaacs have now been published (online ahead of print) and many more are in various stages of review. Those published include:
The Campaign for Alzheimer’s Research in Europe (CARE) has offered to sponsor travel bursaries for UK or Irish students or postdocs to attend the 2018 NECTAR meeting, to be held 6-7 December 2018 in Paris.
Applications will be competitive and are open to PhD students and post-docs (but not salaried faculty) from any NECTAR member laboratories within the UK and Ireland, and will be for a max of £350 (UK) or €400 (Ireland) each. The applicant must submit an abstract for a data-blitz or invited oral presentation at the meeting. The subject may be in any area of neurorestoration or transplantation for neurodegenerative disease, although applications that focus on Alzheimer’s disease and dementia are particularly welcomed.
We are delighted to announce that the incoming NECTAR President is Dr Agnete Kirkeby from the University of Copenhagen. Dr Kirekeby will take over the role at the NECTAR2018 meeting in Paris in December. Congratulations to Agnete and we wish her the very best in her new role!
Agnete performed part her graduate research project partly at the pharmaceutical company H. Lundbeck and partly with the field pioneer Lorenz Studer at the Sloan Kettering Institute (New York). In 2009 she went on to perform her postdoc in the group of Malin Parmar at Lund University (Sweden) where she over the years built up a unique expertise in using human pluripotent stem cells for production of subtype-specific neural cells and developing protocols for accurate patterning of neural cells towards different regional fates (Kirkeby et al., Cell Reports 2012). This work has led to the development of a promising stem cell treatment for Parkinson’s Disease (PD) (Grealish et al., Cell Stem Cell 2014, Grealish et al. Stem Cell Reports 2015), which is currently in translation to the clinic in collaboration with Prof. Malin Parmar and Prof. Roger Barker (Kirkeby et al., Cell Stem Cell 2017, Nolbrant et al., Nature Protocols 2017, Kirkeby et al., Prog. Brain Research 2017). Agnete started her own group in 2015 at Lund University and has built up her own line of research by combining stem cell patterning protocols with microfluidic techniques to produce in vitro 3D models of the human developing brain. Based on a junior group leader start-up package from the Novo Nordisk Foundation Center for Stem Cell Biology (DanStem), she moved her group to the University of Copenhagen in the beginning of 2017.